{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"14"},{"groupId":"OG003","value":"13"}],"units":"Participants"}],"description":"A DLT was defined as occurrence of any treatment-emergent adverse event (TEAE) in Phase 1 Parts 1 and 2. DLT included all TEAE of specified grades such as 1) Hematologic toxicities - any Grade 4 thrombocytopenia or neutropenia, anemia, febrile neutropenia, ≥ Grade 3 hemolysis, thrombocytopenia and 2) Nonhematologic toxicities - Grade 4 AE, nausea, vomiting, or diarrhea, electrolyte abnormality, ≥ Grade 3 aspartate aminotransferase (AST), alanine aminotransferase (ALT), or total bilirubin elevation, Grade 2 AST/ALT with symptomatic liver inflammation, AST or ALT \\> 3 × upper limit of normal (ULN) and concurrent total bilirubin \\> 2 × ULN without initial findings of cholestasis, and any other ≥ Grade 3 toxicity. A TEAE is any AE either reported for the first time or worsening of a pre-existing event after first dose of study drug and up to 100 days after last dose of study drug.","groups":[{"description":"Participants received epacadostat 25 mg, orally, BID in combination of nivolumab 3 mg/kg, IV, on Days 1, 15, 29, and 43 of each 8-week cycle.","id":"OG000","title":"Phase 1, Part 1: Epacadostat 25 mg + Nivolumab 3 mg"},{"description":"Participants received epacadostat 50 mg, orally, BID in combination of nivolumab 3 mg/kg, IV, Q3W, on Days 1, 15, 29, and 43 of each 8-week cycle.","id":"OG001","title":"Phase 1, Part 1: Epacadostat 50 mg + Nivolumab 3 mg"},{"description":"Participants received epacadostat 100 mg, orally, BID in combination of nivolumab 3 mg/kg, IV, Q3W, on Days 1, 15, 29, and 43 of each 8-week cycle.","id":"OG002","title":"Phase 1, Part 1: Epacadostat 100 mg + Nivolumab 3 mg"},{"description":"Participants received epacadostat 300 mg, orally, BID in combination of nivolumab 3 mg/kg, IV, Q3W, on Days 1, 15, 29, and 43 of each 8-week cycle.","id":"OG003","title":"Phase 1, Part 1: Epacadostat 300 mg + Nivolumab 3 mg"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"The Phase 1, Part 1 Safety Population includes all participants enrolled in the study who received at least 1 dose of study drug.","reportingStatus":"POSTED","timeFrame":"Day 42","title":"Phase 1, Part 1: Number of Participants With Dose Limiting Toxicities (DLTs)","type":"PRIMARY","unitOfMeasure":"Participants"}